Clinical trials: Stage 2 Hypertension
Glaucoma
Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930
This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects
- Trial name
- NCT05207761
- Testing
- D565, D930
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of…
- Trial name
- NCT00168779
- Testing
- telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg
- Where
- 113 sites in United States
- Volunteers
- 1,185 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
The purpose of this study is to learn whether dapagliflozin, after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an angiotensin-converting enzyme…
- Trial name
- NCT01137474
- Testing
- Dapagliflozin
- Where
- 329 sites in United States, Canada and 14 more
- Volunteers
- 2,996 people
- Sponsor
- AstraZeneca
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT06744426
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Mild Hypertension
A Study in People With Mild Hypertension
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
- Trial name
- NCT00374855
- Testing
- PPAR alpha, Hydrochlorothiazide
- Where
- 10 sites in Sweden
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Hypertension
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with…
- Trial name
- AIMS (NCT00797316)
- Testing
- Aliskiren, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Novartis
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM…
- Trial name
- NCT04405245
- Testing
- Latanoprost ophthalmic solution, AKB-9778 4%
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Hypertension
Aliskiren Study of Safety and Efficacy in Senior Hypertensives
This study is designed to compare the blood pressure lowering efficacy of aliskiren, a combination of aliskiren plus amlodipine, and ramipril in elderly patients with mild to moderate hypertension.
- Trial name
- ASSESS (NCT01922141)
- Testing
- Aliskiren, Amlodipine, Ramipril
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
- Trial name
- ATLAAST (NCT00739596)
- Testing
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Diabetes Mellitus, Type 2, Essential Hypertension
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.
- Trial name
- NCT00328965
- Testing
- Lacidipine
- Sponsor
- GlaxoSmithKline
Ocular Hypertension, Open Angle Glaucoma
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
- Trial name
- NCT01731002
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- 22 sites in United States
- Volunteers
- 224 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Glaucoma, Ocular Hypertension (OH)
A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate the efficacy, safety and duration of the L-PPDS (latanoprost punctal plug delivery system) at different dose levels.
- Trial name
- NCT01481051
- Testing
- Latanoprost-PPDS
- Where
- 6 sites in United States
- Volunteers
- 57 people
- Sponsor
- Mati Therapeutics Inc.
Pulmonary Arterial Hypertension
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07143448
- Testing
- HS235
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 90 people
- Sponsor
- 35Pharma Inc., a GSK company
Hypertension
Effectiveness of a Valsartan Based Versus an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
The population for this current study will include stage 1 and stage 2 hypertensive patients who are newly diagnosed or didn't have treatment during the last 3 months and patients who are currently treated but uncontrolled on…
- Trial name
- NCT00304226
- Testing
- valsartan, amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,288 people, healthy volunteers welcome
- Sponsor
- Novartis
Open Angle Glaucoma, Ocular Hypertension
Next Generation Rocklatan
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT06441643
- Testing
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 426 people
- Sponsor
- Alcon Research
Hypertension
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
- Trial name
- NCT00362115
- Testing
- Azilsartan Medoxomil, Olmesartan
- Where
- 54 sites in United States, Argentina and 2 more
- Volunteers
- 449 people
- Sponsor
- Takeda
Hypertension
Effect of Febuxostat on Blood Pressure
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo on lowering ambulatory 24-hour mean blood pressure of participants with hypertension and hyperuricemia (not associated with…
- Trial name
- NCT01496469
- Testing
- Febuxostat
- Where
- 45 sites in United States
- Volunteers
- 121 people
- Sponsor
- Takeda